摘要
目的:观察黄芪的抗肝纤维化作用,初步探讨黄芪抗肝纤维化的机制。方法:设立正常对照组、模型组和黄芪处理组,以四氯化碳(CCl4)皮下注射复制大鼠肝纤维化模型,黄芪处理组在造模的同时给予皮下注射黄芪注射液。常规HE染色观察肝脏病变,天狼猩红胶原染色、肝组织羟脯氨酸(HYP)含量测定观察肝纤维化程度;产色基质偶氮法鲎试剂定量测定血浆内毒素,赖氏法测定血浆丙氨酸氨基转移酶(ALT);TBA法检测肝组织丙二醛(MDA)水平。结果:黄芪处理组与模型组比较,①肝脏的损伤性改变有所减轻,肝组织HYP及肝纤维化指数(FI)明显降低;②血浆内毒素含量、ALT及肝组织MDA均有不同程度的降低。结论:黄芪可减缓肠源性内毒素血症,可能为防治肝纤维化的作用机制之一。
Objective： To observe the action of Astragalus on anti-hepatic fibrosis, in order to probe into the mechanism of Astragalus in resisting hepatic fibrosis. Methods： Normal control group, model group and Astragalus treatment group were set in the experiment, model of hepatic fibrosis was induced by subcutaneous injection of carbon tetrachloride （CCl 4）. Astra- galus treatment group was given subcutaneous Astragalus when establishing models. Liver tissues were stained with hema - toxylin-erosin to observe liver injury. The degree of liver fibrosis was observed by stained of sirius red of collagen and the content of hydroxyproline in liver tissues. Endotoxin was measured with a limulus amebocyte lysate test kit. Plasma alanine aminotransferase （ALT） was determined with Reitman-Frankel method; the content of malondialdehyde （MDA） in liver tis - sue was determined with TBA method. Results： Astragalus treatment group compared with model group： ①changes in liver damage were relieved, HYP in liver tissue and hepatic fibrosis index （FI） were significantly reduced; ②plasma endotoxin, ALT and liver MDA were reduced to different degrees. Conclusion： Astragalus can alleviate CCl4-induced liver injury, stave happening and developing of hepatic fibrosis; Astragalus can reduce intestinal endotoxemia, which may be one of the mechanisms contributing to the prevention and treatment of Astragalus on liver fibrosis.
出处
《中国医药导报》
CAS
2010年第9期15-17,共3页
China Medical Herald
关键词
内毒素
肝纤维化
黄芪
Endotoxin
Hepatic fibrosis
Astragalus
